Gilead's Biktarvy Set For EU Approval
A combination therapy – Gilead Science’s Biktarvy – a hybrid medicine and a generic can look forward to EU approval after getting the OK from the EMA’s drug evaluation committee last week.
A combination therapy – Gilead Science’s Biktarvy – a hybrid medicine and a generic can look forward to EU approval after getting the OK from the EMA’s drug evaluation committee last week.